Glaxosmithkline plc - ADR

GSK

$41.37

+18.2% (1 year change)

Ken Fisher Holding value: $738 Million Jim Simons Holding value: $389 Million Ken Griffin Holding value: $20.5 Million Jeremy Grantham Holding value: $12 Million Ray Dalio Holding value: $4.95 Million Mario Gabelli Holding value: $1.1 Million Joel Greenblatt Holding value: $0 Tom Russo Holding value: $0 Chris Davis Holding value: $0 Prem Watsa Holding value: $0 Warren Buffett Holding value: $0

Market Cap

$105 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$32.26 - $43.07

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

16.11x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$2.16 (5.19%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $105 Billion
Enterprise Value $134 Billion
Dividend Yield $2.16 (5.19%)
1 Year Return +23.4%
52-Week High $43.07
52-Week Low $32.26
Beta 0.4
Outstanding Shares 2.52 Billion
Avg 30 Day Volume 4.65 Million

Valuation

P/E Ratio 16.11
PEG -966.09
Earnings per Share $2.57
Price to Sales Ratio 2.18
Price to Book Ratio 5.17
Revenue to Enterprise Value 2.78
EBIT to Enterprise Value 18.06
Total Debt to Enterprise Value 0.26
Debt to Equity 1.66

Profitability

Revenue $48.4 Billion
Gross Profit $32.3 Billion
EBIT $7.44 Billion
Net Income $6.5 Billion
Profit Margin 13.43%
Quarterly Earnings Growth (YoY) -1.7%
Return on Equity 31.32%
Return on Assets 6.14%
Return on Invested Capital 9.83%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About Glaxosmithkline plc - ADR

CEO: Emma Walmsley

Industry: Medicinal and Botanical Manufacturing

Similar stocks

Astrazeneca plc - ADR
Pfizer Inc.
Merck & Co Inc
Novartis AG - ADR
Sanofi - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Dynavax Technologies Corp.

News

VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021

VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021

Kwhen Finance Kwhen Finance, about 22 hours ago
GSK poaches vaccine executive from Pfizer

GSK poaches vaccine executive from Pfizer

GlaxoSmithKline has poached a Pfizer vaccine executive after failing to bring its own Covid jab to market during the pandemic.

City AM City AM, 2 days ago
GlaxoSmithKline ready for human trials of HIV cure

GlaxoSmithKline ready for human trials of HIV cure

GSK, which hopes to start ground-breaking trials as soon as next summer, will provide an update to the City on its potential cure for the disease.

Daily Mail Online Daily Mail Online, 4 days ago
GlaxoSmithKlines (GSK) Buy Rating Reaffirmed at Berenberg Bank

GlaxoSmithKlines (GSK) Buy Rating Reaffirmed at Berenberg Bank

Berenberg Bank restated their buy rating on shares of GlaxoSmithKline (NYSE:GSK) in a research note published on Wednesday morning, The Fly reports. GSK has ...

Dakota Financial News Dakota Financial News, 4 days ago
To improve your user experience we use cookies.